Finance

Beta
Lists
317450:KRX
Myung In Pharm Co Ltd
₩42,550.00
-0.12%
(-50.00) 1D
Jul 16, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 317450...
Open
₩43,000
High
₩43,600
Low
₩42,200
Mkt. cap
621.23B
Avg. vol.
20.69K
Volume
11.45K
Dividend
3.53%
Quarterly dividend
₩375
Ex-dividend date
Dec 29, 2025
P/E ratio
4.61
52-wk high
₩134,500
52-wk low
₩39,100
EPS
₩9,225
Shares outstanding
14.60M
Open
₩43,000
High
₩43,600
Low
₩42,200
Mkt. cap
621.23B
Avg. vol.
20.69K
Volume
11.45K
Dividend
3.53%
Quarterly dividend
₩375
Ex-dividend date
Dec 29, 2025
P/E ratio
4.61
52-wk high
₩134,500
52-wk low
₩39,100
EPS
₩9,225
Shares outstanding
14.60M
News stories
From sources across the web
About Myung In Pharm Co Ltd
CEOLee Hang Myung | Kim Jae-hyuk | Ko Dong-kyu
Employees-
FoundedApr 1985
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Mar 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
70.25B
72.70B
72.09B
72.14B
Cost of goods sold
29.01B
28.31B
28.44B
27.56B
Cost of revenue
29.01B
28.31B
28.44B
27.56B
Research and development expenses
986.99M
1.37B
1.42B
1.10B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.48B
19.79B
17.14B
17.47B
Operating expense
19.48B
22.48B
19.98B
19.47B
Total operating expenses
48.50B
50.78B
48.42B
47.03B
Operating income
21.76B
21.91B
23.67B
25.11B
Other non operating income
86.91M
206.58M
15.97M
446.90M
EBT including unusual items
24.22B
24.11B
26.79B
30.04B
EBT excluding unusual items
24.22B
24.11B
26.77B
30.04B
Income tax expense
5.59B
5.56B
3.53B
7.31B
Effective tax rate
23.06%
23.05%
13.20%
24.32%
Other operating expenses
278.96M
614.50M
533.43M
318.66M
Net income
18.64B
18.55B
23.25B
22.73B
Net profit margin
26.53%
25.51%
32.25%
31.51%
Earnings per share
-
-
-
-
Interest and investment income
2.13B
1.72B
3.26B
3.55B
Interest expense
-62.44M
-57.80M
-55.11M
-54.73M
Net interest expenses
2.06B
1.67B
3.20B
3.50B
Depreciation and amortization charges
642.86M
636.54M
648.53M
612.05M
EBITDA
24.73B
24.47B
26.18B
27.62B
Gain or loss from assets sale
-
904.00K
-21.89M
-
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more